




Correction to: Association of PD-L1 and IDO1 expression with JAK–STAT pathway activation in soft-tissue leiomyosarcoma

Takeshi Iwasaki^{1,2} · Kenichi Kohashi¹ · Yu Toda¹ · Shin Ishihara¹ · Yuichi Yamada¹ · Yoshinao Oda¹ 

Published online: 24 November 2020

© Springer-Verlag GmbH Germany, part of Springer Nature 2020

Correction to:

Journal of Cancer Research and Clinical Oncology

<https://doi.org/10.1007/s00432-020-03390-9>

In the original article published, the data of AJCC stage in Tables 1 and 2 were in AJCC 7th edition. There is no change in the conclusion, but we would like to update the data of Tables 1 and 2 to AJCC 8th edition.

The original article can be found online at <https://doi.org/10.1007/s00432-020-03390-9>.

✉ Yoshinao Oda
oda@surgpath.med.kyushu-u.ac.jp

¹ Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka 812-8582, Fukuoka, Japan

² Department of Diagnostic Pathology, Japan Community Healthcare Organization, Kyushu Hospital, 1-8-1, Kishinoura, Yahatanishi-ku, Kitakyushu 806-8501, Fukuoka, Japan

Table 1 Correlations of clinicopathological characteristics with PD-L1, IDO1, pJAK2 and TDO2 immunoeexpression

	n (%)	PD-L1		IDO1		pJAK2		TDO2		P-value
		< 1% (-)	≥ 1% (+)	< 1% (-)	≥ 1% (+)	Low (H-score < 107)	High (H-score ≥ 107)	Low (H-score < 50)	High (H-score ≥ 50)	
Age (n[%])										
≥ 60	40 (58%)	31	9	14	26	14	18	20	12	0.4785
< 60	29 (42%)	22	7	13	16	16	21	20	17	
Sex (n[%])										
Female	31 (45%)	24	7	12	19	14	17	17	14	0.6341
Male	38 (55%)	29	9	15	23	16	22	23	15	
Mitotic score (n[%])										
1	29 (42%)	24	5	12	17	12	17	24	5	0.0011*
2	19 (28%)	14	5	6	13	11	8	7	12	
3	21 (30%)	15	6	9	12	7	14	9	12	
Location (n[%])										
Upper extremities	5 (7%)	4	1	0	5	2	3	2	3	0.7460
Lower extremities	24 (35%)	16	8	9	15	10	14	15	9	
Trunk	40 (58%)	33	7	18	22	18	22	23	17	
Subtype (n[%])										
L	40 (58%)	33	7	17	23	19	21	28	12	0.0538 [†]
M	3 (4%)	3	0	2	1	1	2	2	1	
P	22 (32%)	14	8	7	15	8	14	9	13	
GC	4 (6%)	3	1	1	3	2	2	1	3	
AJCC stage 8th ed. (n[%])										
I	13 (19%)	12	1	5	8	8	5	10	3	0.1791
II	16 (23%)	11	5	4	12	5	11	6	10	
III	32 (48%)	22	10	14	18	15	17	20	12	
IV	6 (9%)	6	0	4	2	2	4	4	2	
NA	2									
Chemotherapy (n[%])										
Yes	10 (14%)	9	1	6	4	7	3	5	5	0.6539
No	59 (86%)	44	15	21	38	33	26	25	34	
FNCLCC (n[%])										
1	16 (23%)	15	1	7	9	8	8	13	3	0.1086
2	32 (46%)	22	10	11	21	14	18	16	16	
3	21 (30%)	16	5	9	12	8	13	11	10	

L conventional LMS, M myxoid LMS, P pleomorphic LMS, GC giant cell LMS, NA not available

*P < 0.05, [†]P < 0.1

Table 2 Univariate Cox regression analyses of the relationships of prognosis with clinicopathological factors and IHC results

Analyzed group	Overall survival		Progression free survival	
	Univariate	<i>P</i> -value	Univariate	<i>P</i> -value
	HR (95% CI)		HR (95% CI)	
Age (≥ 60 / < 60)	0.99 (0.49–2.00)	0.9716	1.56 (0.84–2.90)	0.1571
Sex (Male/Female)	0.84 (0.41–1.70)	0.6264	0.81 (0.44–1.48)	0.4844
Histological subtype				
GC/L	8.24 (2.13–31.85)	0.0022*	8.21 (2.16–31.23)	0.0020*
P/L	2.99 (1.34–6.67)	0.0074*	1.97 (1.02–3.84)	0.0452*
M/L	7.32 (1.99–26.95)	0.0028*	2.53 (0.74–8.64)	0.1373
AJCC stage 8th ed. (III + IV/I + II)	1.81 (0.83–3.93)	0.1354	1.59 (0.83–3.02)	0.1582
FNCLCC				
Grade 2/ grade 1	1.83 (0.60–5.58)	0.2873	0.99 (0.44–2.28)	0.9889
Grade 3/ grade 2	2.71 (1.23–5.93)	0.0129*	1.73 (0.87–3.43)	0.1184
Chemotherapy (Yes/No)	1.24 (0.53–2.89)	0.6182	1.22 (0.56–2.67)	0.6097
PD-L1 ($\geq 1\%$ / $< 1\%$)	1.06 (0.45–2.48)	0.8923	0.84 (0.40–1.76)	0.6457
IDO1 ($\geq 1\%$ / $< 1\%$)	0.79 (0.39–1.59)	0.5062	0.85 (0.46–1.56)	0.5936
pJAK2 (Hscore ≥ 107 / < 107)	1.66 (0.79–3.46)	0.1795	1.00 (0.55–1.84)	0.9916
TDO2 (Hscore ≥ 50 / < 50)	1.23 (0.61–2.51)	0.5581	1.00 (0.54–1.85)	0.9987

L conventional LMS, *GC* giant cell LMS, *P* pleomorphic LMS, *M* myxoid LMS

**P* < 0.05

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.